Aquestive Therapeutics to Participate in Two Upcoming Investor Conferences

Rhea-AI Summary

Aquestive Therapeutics (NASDAQ:AQST) has announced its participation in two major healthcare investor conferences. The company will attend the Jefferies London Annual Healthcare Conference from November 19-21, 2024, offering one-on-one meetings with management. Additionally, they will participate in Piper Sandler's 35th Annual Healthcare Conference on December 4th, 2024, featuring a fireside chat at 1:30 PM ET and one-on-one meeting opportunities.

The Piper Sandler presentation will be webcast and available on the company's website under the 'Events and Presentation' section, with replay access for 30 days post-event.

WAQRREN, N.J., Nov. 12, 2024 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ:AQST) ("Aquestive" or the "Company"), a pharmaceutical company advancing medicines to bring meaningful improvement to patients' lives through innovative science and delivery technologies, announced today that the management team will participate in two upcoming investor conferences in November and December 2024 as follows:

• Jefferies London Annual Healthcare Conference: management will be available for 1x1 meetings on Tuesday, November 19^th through Thursday, November 21^st
• Piper Sandler’s 35^th Annual Healthcare Conference: fireside chat to take place on Wednesday, December 4^th at 1:30pm ET; management will also be available for 1x1 meetings

A webcast of the presentation at the Piper Sandler 35^th Annual Healthcare Conference will be available under the “Events and Presentation” page of the Investors section of the Company’s website. A replay of the webcast will be available for 30 days following the event. For more information, please visit investors.aquestive.com.

About Aquestive Therapeutics, Inc.
Aquestive is pharmaceutical company advancing medicines to bring meaningful improvement to patients' lives through innovative science and delivery technologies. We are developing orally administered products to deliver complex molecules, providing novel alternatives to invasive and inconvenient standard of care therapies. Aquestive has five commercialized products marketed by the Company and its licensees in the U.S. and around the world and is the exclusive manufacturer of these licensed products. The Company also collaborates with pharmaceutical companies to bring new molecules to market using proprietary, best-in-class technologies, like PharmFilm^®, and has proven drug development and commercialization capabilities. Aquestive is advancing a late-stage proprietary product candidate for the treatment of severe allergic reactions, including anaphylaxis, and an early-stage epinephrine prodrug topical gel product candidates for various possible dermatology conditions. For more information, visit Aquestive.com and follow us on LinkedIn.

Forward Looking Statement
This press release contains certain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as “believe,” “anticipate,” “plan,” “expect,” “estimate,” “intend,” “may,” “will,” or the negative of those terms, and similar expressions, are intended to identify forward-looking statements. These forward-looking statements are based on the Company’s current expectations and beliefs and are subject to a number of risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. Such risks and uncertainties include, but are not limited to, risks associated with the Company’s development work, including any delays or changes to the timing, cost and success of its product development activities and clinical trials and other risks and uncertainties affecting the Company described in the “Risk Factors” section and in other sections included in its Annual Report on Form 10-K, Quarterly Reports on Form 10-Q, and Current Reports on Form 8-K filed with the U.S. Securities and Exchange Commission. Given those uncertainties, you should not place undue reliance on these forward-looking statements, which speak only as of the date made. All subsequent forward-looking statements attributable to the Company or any person acting on its behalf are expressly qualified in their entirety by this cautionary statement. The Company assumes no obligation to update forward-looking statements or outlook or guidance after the date of this press release whether as a result of new information, future events or otherwise, except as may be required by applicable law.

Investor Contact:
Brian Korb
astr partners
brian.korb@astrpartners.com

FAQ

When is Aquestive Therapeutics (AQST) presenting at the Piper Sandler Healthcare Conference in 2024?

Aquestive Therapeutics will present a fireside chat at Piper Sandler's 35th Annual Healthcare Conference on December 4th, 2024, at 1:30 PM ET.

Which investor conferences is Aquestive Therapeutics (AQST) attending in late 2024?

Aquestive Therapeutics is attending the Jefferies London Annual Healthcare Conference (November 19-21, 2024) and Piper Sandler's 35th Annual Healthcare Conference (December 4, 2024).

How long will the webcast replay be available for Aquestive's (AQST) Piper Sandler presentation?

The webcast replay will be available for 30 days following the event on the company's website under the 'Events and Presentation' page.